Promising new drug trial for rare inflammatory disease VEXAS
NCT ID NCT07569081
First seen May 09, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This study tests a drug called momelotinib in 192 adults with VEXAS syndrome, a rare and serious inflammatory condition caused by a genetic mutation. The goal is to see if the drug can reduce disease activity, with participants receiving either momelotinib or a placebo. The trial is not yet recruiting and requires a confirmed UBA1 gene mutation and active inflammation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VEXAS SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.